| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/10/2006 | CA2129897C Coa-it and paf inhibitors |
| 01/05/2006 | WO2006001471A1 Medicinal composition for promoting glucose-responsive insulin secretion |
| 01/05/2006 | WO2003087338A3 Her-2 receptor tyrosine kinase molecules and uses thereof |
| 01/05/2006 | WO2003031406A3 Kinase inhibitor scaffolds and methods for their preparation |
| 01/05/2006 | WO2003016493A3 Transporters and ion channels |
| 01/05/2006 | US20060004706 Method of forming molecule function network |
| 01/05/2006 | US20060004084 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 01/05/2006 | US20060004080 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto |
| 01/05/2006 | US20060004078 N-hydroxyformamidine derivatives |
| 01/05/2006 | US20060004077 Inhibiting class II MHC-mediated activation of T cells; peptidomimetics of given sequence which include a Gpg (guanylpiperidyl glycine) unit; rheumatoid arthritis and/or multiple sclerosis; e.g. Ac-Cha-Gpg-Tic-Nle-NHCH2CH2Ph (Cha=cyclohexylalanine, Tic=3-carboxyisoquinoline, Nle=norleucine) |
| 01/05/2006 | US20060004073 Compounds, compositions, and methods |
| 01/05/2006 | US20060004062 Compounds for inhibiting insulin secretion and methods related thereto |
| 01/05/2006 | US20060004056 Di-aryl-substituted-ethan pyridone pde4 inhibitors |
| 01/05/2006 | US20060004054 Administering 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline before or at the time angioplasty, coronary by-pass grafting or stent implantation |
| 01/05/2006 | US20060004033 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 01/05/2006 | US20060004029 Nitrogen-containing aromatic derivatives |
| 01/05/2006 | US20060004028 Novel PARP inhibitor |
| 01/05/2006 | US20060004025 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 01/05/2006 | US20060004023 Treatment for attention-deficit hyperactivity disorder |
| 01/05/2006 | US20060004020 Pyrrolidine derivatives as oxytocin antagonists |
| 01/05/2006 | US20060004013 Cinnamide compound |
| 01/05/2006 | US20060004010 Ccr4 antagonist and medical use thereof |
| 01/05/2006 | US20060003988 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2006 | US20060003987 Compounds and their uses |
| 01/05/2006 | US20060003984 Monobactam compositions and methods of use thereof |
| 01/05/2006 | US20060003978 beta-secretase inhibitors; to reduce A beta peptide formation; to reduce amyloid beta deposits or plaques; 12-[2-(3-Ethyl-benzylamino)-1-hydroxy-ethyl]-16-fluoro-2-oxa-8,11-diaza-bicyclo[12.3.1]octadeca-1(17),14(18),15-triene-7,10-dione |
| 01/05/2006 | US20060003975 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor |
| 01/05/2006 | US20060003955 Immunostimulatory nucleic acid molecules |
| 01/05/2006 | US20060003954 Inhibiting the expression of a wild type COL1A1 gene to treat a lung disease relating to a collagen disorder |
| 01/05/2006 | US20060003946 Tissue-penetrating property, and exhibits high selectivity to tumor cells and hydrophilicity |
| 01/05/2006 | US20060003937 Urocortin-III and uses thereof |
| 01/05/2006 | US20060003934 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 01/05/2006 | US20060003932 Method for promoting neovascularization |
| 01/05/2006 | US20060003928 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 01/05/2006 | US20060003919 Cosmetic/dermatological applications of LIF |
| 01/05/2006 | US20060003915 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/05/2006 | US20060003419 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003418 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003417 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 01/05/2006 | US20060003410 Oxidoreductase for use in identifying modulators for prevention and treatment of diabetes, obesity, dyslipidemia, coronary heart, inflammatory and cancer disorders |
| 01/05/2006 | US20060003379 Smad6 and uses thereof |
| 01/05/2006 | US20060003378 Expressed by keratinocytes, wound-healing and chondrosarcoma tissue; nucleic acids comprising polynucleotide of given sequence; use in diagnostics and therapeutics |
| 01/05/2006 | US20060003326 Bioconjugation; spiegelmers, aptamers |
| 01/05/2006 | US20060003025 comprising from 1300 to 1500 mg/l of Na+, from 4500 to 6500 mg/l of K+, from 50 to 1300 mg/l of Mg++, from 20 to 350 mg/l of ca++, from 4000 to 6000 mg/l of Cl-, a pH of from 4-9, and an osmolality of from 150-700 mOsm/kg; for treating and cleaning the eye |
| 01/05/2006 | US20060003011 Pharmaceutical compositions of drugs and neutralized acidic polymers |
| 01/05/2006 | US20060002991 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 01/05/2006 | US20060002983 Muscle building preparation |
| 01/05/2006 | US20060002908 Bifidobacterium in the treatment of inflammatory disease |
| 01/05/2006 | US20060002901 Composition containing eosinophil cationic protein |
| 01/05/2006 | US20060002861 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist |
| 01/05/2006 | DE69828607T2 CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN Quinoline and quinoxaline THE COMPOUNDS OF THE PLATELET FACTOR ABSTAMMMENDEN GROWTH AND / OR PDGF-TYROSINE KINASE AND p56 HEMMEN |
| 01/05/2006 | DE102004028778A1 An oligopeptide, useful for controlling the biological activity of cellular biomolecules, comprising at least one cysteine residue and two alpha helical zones |
| 01/05/2006 | DE102004026135A1 An MHC-Moleküle bindende Tumor-assoziierte Peptide Binding to MHC molecules tumor-associated peptides |
| 01/05/2006 | CA2584493A1 Kinase inhibitors for treating cancers |
| 01/05/2006 | CA2572135A1 Sulfonamide compound |
| 01/05/2006 | CA2571852A1 Inhibition of infiltration, and cell killing agent |
| 01/04/2006 | EP1612281A2 Methods for assessing patients with acute myeloid leukemia |
| 01/04/2006 | EP1612273A1 Novel physiologically active substances pf1270a, b and c |
| 01/04/2006 | EP1612272A2 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 01/04/2006 | EP1612266A2 Prostaglandin reductase |
| 01/04/2006 | EP1612265A2 Bioengineered tissue constructs and methods for producing and using them |
| 01/04/2006 | EP1612222A2 Olfactory and pheromones G-protein coupled receptors |
| 01/04/2006 | EP1612208A2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 01/04/2006 | EP1612201A1 Novel shogaol compound and tyrosinase activity inhibitor comprising the compound |
| 01/04/2006 | EP1611901A1 Preventive or remedy for teeth grinding |
| 01/04/2006 | EP1611900A1 Method of treating inflammtory disease associated with bone destruction |
| 01/04/2006 | EP1611899A1 Combined use of g-csf with angiogenetic factor |
| 01/04/2006 | EP1611894A1 Use of n-acetyl-d-aminoglycosamine in treatment of non-specific inflammations related to physical or chemical factors |
| 01/04/2006 | EP1611887A2 Modulation of peroxisome proliferator-activated receptors |
| 01/04/2006 | EP1611144A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| 01/04/2006 | EP1610800A2 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/04/2006 | EP1536800B1 Synergistic interaction of abacavir and alovudine |
| 01/04/2006 | EP1494658B1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| 01/04/2006 | EP1434762A4 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/04/2006 | EP1397153A4 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 01/04/2006 | EP1395585B1 Antibacterial agents |
| 01/04/2006 | EP1363873A4 Peptide deformylase inhibitors |
| 01/04/2006 | EP1351688A4 Urotensin-ii receptor antagonists |
| 01/04/2006 | EP1311677B1 Regulation of human p2y1-like g protein-coupled receptor |
| 01/04/2006 | EP1294725B1 Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 01/04/2006 | EP1294390B1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| 01/04/2006 | EP1265621B1 Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
| 01/04/2006 | EP1250422B1 Myeloid colony stimulating factor and uses thereof |
| 01/04/2006 | EP1242403B1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 01/04/2006 | EP1237553B1 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist |
| 01/04/2006 | EP1212000B1 System for controlling body temperature while reducing shivering |
| 01/04/2006 | EP1202744B1 PRODUCTION OF rhPBGD |
| 01/04/2006 | EP1178834B1 Controlled release of growth factors from heparin containing matrices |
| 01/04/2006 | EP1169298B1 Pharmaceutical compounds |
| 01/04/2006 | EP1150995B1 A synthetic peptide disturbing intracellular signaling |
| 01/04/2006 | EP1147088B1 6-arylphenanthridines with pde-iv inhibiting activity |
| 01/04/2006 | EP1146881B1 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 01/04/2006 | EP1102755B1 Substituted isoxazole derivatives as estrogen receptor modulators |
| 01/04/2006 | EP1083898B1 Novel use of hiv protease inhibiting compounds |
| 01/04/2006 | EP1077728B1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy |
| 01/04/2006 | EP1070083B1 Crystalline forms of 1s- [1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9- [[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino [1, 2-a][ 1,2] diazepine-1-carboxamide |
| 01/04/2006 | EP0932399B1 Water soluble paclitaxel prodrugs |
| 01/04/2006 | CN1717409A Pyrazolonaphthyridine derivative |
| 01/04/2006 | CN1717407A Indolyl derivatives |
| 01/04/2006 | CN1717245A Medicinal composition |